Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy

Hagen S, Baumann T, Wagner HJ, Morath V, Kaufmann B, Fischer A, Bergmann S, Schindler P, Arndt KM, Müller K (2014)
Scientific Reports 4(1): 3759.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Hagen, Sven; Baumann, Tobias; Wagner, Hanna J.; Morath, Volker; Kaufmann, Beate; Fischer, Adrian; Bergmann, Stefan; Schindler, Patrick; Arndt, Katja M.; Müller, KristianUniBi
Abstract / Bemerkung
The pre-clinical and clinical development of viral vehicles for gene transfer increased in recent years, and a recombinant adeno-associated virus (rAAV) drug took center stage upon approval in the European Union. However, lack of standardization, inefficient purification methods and complicated retargeting limit general usability. We address these obstacles by fusing rAAV-2 capsids with two modular targeting molecules (DARPin or Affibody) specific for a cancer cell-surface marker (EGFR) while simultaneously including an affinity tag (His-tag) in a surface-exposed loop. Equipping these particles with genes coding for prodrug converting enzymes (thymidine kinase or cytosine deaminase) we demonstrate tumor marker specific transduction and prodrug-dependent apoptosis of cancer cells. Coding terminal and loop modifications in one gene enabled specific and scalable purification. Our genetic parts for viral production adhere to a standardized cloning strategy facilitating rapid prototyping of virus directed enzyme prodrug therapy (VDEPT).
Scientific Reports
Page URI


Hagen S, Baumann T, Wagner HJ, et al. Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy. Scientific Reports. 2014;4(1): 3759.
Hagen, S., Baumann, T., Wagner, H. J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., et al. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy. Scientific Reports, 4(1), 3759. doi:10.1038/srep03759
Hagen, S., Baumann, T., Wagner, H. J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K. M., and Müller, K. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy. Scientific Reports 4:3759.
Hagen, S., et al., 2014. Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy. Scientific Reports, 4(1): 3759.
S. Hagen, et al., “Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy”, Scientific Reports, vol. 4, 2014, : 3759.
Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., Müller, K.: Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy. Scientific Reports. 4, : 3759 (2014).
Hagen, Sven, Baumann, Tobias, Wagner, Hanna J., Morath, Volker, Kaufmann, Beate, Fischer, Adrian, Bergmann, Stefan, Schindler, Patrick, Arndt, Katja M., and Müller, Kristian. “Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy”. Scientific Reports 4.1 (2014): 3759.

5 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors.
Büning H, Srivastava A., Mol Ther Methods Clin Dev 12(), 2019
PMID: 30815511
Affibody Molecules in Biotechnological and Medical Applications.
Ståhl S, Gräslund T, Eriksson Karlström A, Frejd FY, Nygren PÅ, Löfblom J., Trends Biotechnol 35(8), 2017
PMID: 28514998
Virus-directed enzyme prodrug therapy and the assessment of the cytotoxic impact of some benzimidazole derivatives.
Szewczuk M, Boguszewska K, Żebrowska M, Balcerczak E, Stasiak M, Świątkowska M, Błaszczak-Świątkiewicz K., Tumour Biol 39(7), 2017
PMID: 28752801
Recent progress in protein-protein interaction study for EGFR-targeted therapeutics.
Feiner RC, Müller KM., Expert Rev Proteomics 13(9), 2016
PMID: 27424502
Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors.
Münch RC, Muth A, Muik A, Friedel T, Schmatz J, Dreier B, Trkola A, Plückthun A, Büning H, Buchholz CJ., Nat Commun 6(), 2015
PMID: 25665714

57 References

Daten bereitgestellt von Europe PubMed Central.

Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs
Innovative approaches for enhancing cancer gene therapy.
Bhatia S, Menezes ME, Das SK, Emdad L, Dasgupta S, Wang XY, Sarkar D, Fisher PB., Discov Med 15(84), 2013
PMID: 23725604
In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene.
Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F, Jund R, Mehtali M., Cancer Res. 60(14), 2000
PMID: 10919655
Safety and efficacy of gene transfer for Leber's congenital amaurosis.
Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J., N. Engl. J. Med. 358(21), 2008
PMID: 18441370
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.
Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, Rossi S, Marshall K, Banfi S, Surace EM, Sun J, Redmond TM, Zhu X, Shindler KS, Ying GS, Ziviello C, Acerra C, Wright JF, McDonnell JW, High KA, Bennett J, Auricchio A., Mol. Ther. 18(3), 2009
PMID: 19953081
Will the floodgates open for gene therapy?
AUTHOR UNKNOWN, Nat. Biotechnol. 30(9), 2012
PMID: 22965028
Gene transfer into the mouse retina mediated by an adeno-associated viral vector.
Ali RR, Reichel MB, Thrasher AJ, Levinsky RJ, Kinnon C, Kanuga N, Hunt DM, Bhattacharya SS., Hum. Mol. Genet. 5(5), 1996
PMID: 8733124
Peroral gene therapy of lactose intolerance using an adeno-associated virus vector.
During MJ, Xu R, Young D, Kaplitt MG, Sherwin RS, Leone P., Nat. Med. 4(10), 1998
PMID: 9771745
Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.
Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne BJ., Proc. Natl. Acad. Sci. U.S.A. 93(24), 1996
PMID: 8943064
Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors.
Koeberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD., Proc. Natl. Acad. Sci. U.S.A. 94(4), 1997
PMID: 9037069
Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations.
Boucas J, Lux K, Huber A, Schievenbusch S, von Freyend MJ, Perabo L, Quadt-Humme S, Odenthal M, Hallek M, Buning H., J Gene Med 11(12), 2009
PMID: 19777441
Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer.
Munch RC, Janicki H, Volker I, Rasbach A, Hallek M, Buning H, Buchholz CJ., Mol. Ther. 21(1), 2012
PMID: 22968478
Engineering targeted viral vectors for gene therapy.
Waehler R, Russell SJ, Curiel DT., Nat. Rev. Genet. 8(8), 2007
PMID: 17607305
Clades of Adeno-associated viruses are widely disseminated in human tissues.
Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM., J. Virol. 78(12), 2004
PMID: 15163731
Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model.
Shirakawa T, Gardner TA, Ko SC, Bander N, Woo S, Gotoh A, Kamidono S, Chung LW, Kao C., J. Urol. 162(3 Pt 1), 1999
PMID: 10458414
Antitumor activity of mutant bacterial cytosine deaminase gene for colon cancer.
Deng LY, Wang JP, Gui ZF, Shen LZ., World J. Gastroenterol. 17(24), 2011
PMID: 21734808
Engineering BioBrick vectors from BioBrick parts.
Shetty RP, Endy D, Knight TF Jr., J Biol Eng 2(), 2008
PMID: 18410688
Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
Friedman M, Orlova A, Johansson E, Eriksson TL, Hoiden-Guthenberg I, Tolmachev V, Nilsson FY, Stahl S., J. Mol. Biol. 376(5), 2008
PMID: 18207161
Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display.
Steiner D, Forrer P, Pluckthun A., J. Mol. Biol. 382(5), 2008
PMID: 18706916
DARPins: a new generation of protein therapeutics.
Stumpp MT, Binz HK, Amstutz P., Drug Discov. Today 13(15-16), 2008
PMID: 18621567
Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas.
Walker RA, Dearing SJ., Breast Cancer Res. Treat. 53(2), 1999
PMID: 10326794
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA., J. Clin. Oncol. 21(20), 2003
PMID: 12953099
Epidermal growth factor receptor and bladder cancer.
Colquhoun AJ, Mellon JK., Postgrad Med J 78(924), 2002
PMID: 12415079
Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.
Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY., FEBS Lett. 584(12), 2010
PMID: 20388508
Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size.
Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, Dreier B, Schibli R, Binz HK, Waibel R, Pluckthun A., Cancer Res. 70(4), 2010
PMID: 20124480
Tumor Targeting by N-terminal Fusion to Virus Capsid. 2013-12-17
Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking.
Lux K, Goerlitz N, Schlemminger S, Perabo L, Goldnau D, Endell J, Leike K, Kofler DM, Finke S, Hallek M, Buning H., J. Virol. 79(18), 2005
PMID: 16140755
Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors.
White SJ, Nicklin SA, Buning H, Brosnan MJ, Leike K, Papadakis ED, Hallek M, Baker AH., Circulation 109(4), 2004
PMID: 14732747
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.
Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, Deleage G, Hallek M., Nat. Med. 5(12), 1999
PMID: 10581091
Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus.
Warrington KH Jr, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N., J. Virol. 78(12), 2004
PMID: 15163751
Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines.
Xu YH, Richert N, Ito S, Merlino GT, Pastan I., Proc. Natl. Acad. Sci. U.S.A. 81(23), 1984
PMID: 6095284
Mechanisms of apoptosis induction by nucleoside analogs.
Sampath D, Rao VA, Plunkett W., Oncogene 22(56), 2003
PMID: 14663485
Prodrugs: a challenge for the drug development.
Zawilska JB, Wojcieszak J, Olejniczak AB., Pharmacol Rep 65(1), 2013
PMID: 23563019
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M., Science 304(5676), 2004
PMID: 15118125
A view on EGFR-targeted therapies from the oncogene-addiction perspective.
Perez R, Crombet T, de Leon J, Moreno E., Front Pharmacol 4(), 2013
PMID: 23637683
Altering AAV tropism with mosaic viral capsids.
Gigout L, Rebollo P, Clement N, Warrington KH Jr, Muzyczka N, Linden RM, Weber T., Mol. Ther. 11(6), 2005
PMID: 15922956
Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.
Morrison J, Briggs SS, Green NK, Thoma C, Fisher KD, Kehoe S, Seymour LW., Hum. Gene Ther. 20(3), 2009
PMID: 19257852
Gene therapy clinical trials worldwide to 2012 - an update.
Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J., J Gene Med 15(2), 2013
PMID: 23355455
Part:pSB1C3. Registry of Standard Biological Parts. 2013-12-17
Polyethylenimine, a cost-effective transfection reagent
Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR.
Rohr UP, Wulf MA, Stahn S, Steidl U, Haas R, Kronenwett R., J. Virol. Methods 106(1), 2002
PMID: 12367732
Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles.
Rohr UP, Heyd F, Neukirchen J, Wulf MA, Queitsch I, Kroener-Lux G, Steidl U, Fenk R, Haas R, Kronenwett R., J. Virol. Methods 127(1), 2005
PMID: 15893564
Genetic analysis of hyperproduction of epidermal growth factor receptors in human epidermoid carcinoma A431 cells.
Shimizu N, Kondo I, Gamou S, Behzadian MA, Shimizu Y., Somat. Cell Mol. Genet. 10(1), 1984
PMID: 6322359


Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®


PMID: 24457557
PubMed | Europe PMC

Suchen in

Google Scholar